GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Total Current Liabilities

iBio (IBIO) Total Current Liabilities : $21.55 Mil (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is iBio Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. iBio's total current liabilities for the quarter that ended in Dec. 2023 was $21.55

iBio Total Current Liabilities Historical Data

The historical data trend for iBio's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Total Current Liabilities Chart

iBio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.46 5.24 6.65 30.44 21.58

iBio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.78 22.28 21.58 20.71 21.55

iBio Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

iBio's Total Current Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.043+13.598
+Other Current Liabilities+Current Deferred Liabilities
=1.941+0
=21.58

iBio's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=6.265+13.352
+Other Current Liabilities+Current Deferred Liabilities
=1.936+0
=21.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

iBio Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of iBio's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

iBio (IBIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Total Current Liabilities
Comparable Companies
LIPO APM CYCC TRVN THER BCLI ERNA KTTA PULM BZYR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
8800 HSC Parkway, Bryan, TX, USA, 77807-1107
Website
https://www.ibioinc.com
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
Executives
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431

iBio (IBIO) Headlines

From GuruFocus

Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?

By PRNewswire PRNewswire • 07-16-2021

Thinking about buying stock in Blackboxstocks, Exela Technologies, iBio, Powerbridge Technologies, or Luminar Technologies?

By PRNewswire PRNewswire • 03-03-2023

Thinking about buying stock in Plug Power, iBio Inc, Aurora Cannabis, Pluristem Therapeutics, or FuelCell Energy?

By PRNewswire PRNewswire • 08-10-2020

Thinking about buying stock in InspireMD, iBio, Nokia, Novan, or T2 Biosystems?

By PRNewswire PRNewswire • 02-08-2021

Thinking about buying stock in Ibio Inc, Gulfport Energy Corporation, Delta Air Lines, Inc., Autoweb Inc, or Etsy Inc?

By PRNewswire PRNewswire • 08-25-2020

Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?

By PRNewswire PRNewswire • 07-22-2020

Thinking about buying stock in iBio, Fluidigm Corp, Atossa Therapeutics, BioCryst Pharmaceuticals, or GameStop?

By PRNewswire PRNewswire • 01-22-2021

Thinking about buying stock in Cinedigm Corp, iBio Inc, Nio Inc, American Airlines, or Chesapeake Energy Corp?

By PRNewswire PRNewswire • 06-04-2020

Thinking about buying stock in VBI Vaccines, Electrameccanica Vehicles, Ibio Inc, American Airlines, or Workhorse Group?

By PRNewswire PRNewswire • 07-08-2020

Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?

By PRNewswire PRNewswire • 06-11-2021